Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pharming Earns Santarus Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Pharming Earns Santarus Milestone

BLA planned for Ruconest

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharming Group and Santarus have met the primary endpoint in a Phase III study of Ruconest (recombinant human C1 esterase inhibitor) for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE), triggering a $10 million milestone payment to Pharming. Pharming is eligible to receive an additional $5 million upon FDA acceptance of the BLA for review. The companies expect to submit the BLA for Ruconest in the 1H13.
 
Sijmen de Vries, Pharming’s chief executive officer, said, “We are pleased to have received this US$10 million milestone from our partner Santarus, which significantly strengthens our balance sheet and signals the beginning of a new chapter in the development of the company.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics